Kunkler Ian
Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland.
Semin Radiat Oncol. 2022 Apr;32(2):155-158. doi: 10.1016/j.semradonc.2021.11.006.
Breast cancer in older patients presents an increasing health care challenge. Hypofractionated dose schedules of 15/16 daily fractions of postoperative radiotherapy over 3/3.5 weeks have been established in clinical trials with long term follow up as safe and effective and become the standard of care after breast conserving therapy for most older patients. Emerging clinical trial data are pushing the limits of hypofractionation to even shorter schedules over a week. In this mini-review the applicability of this new data to older patients is discussed and the development of guidelines for hypofractionated dose fractionation schedules adapted to the COVID19 pandemic for this age group.
老年患者的乳腺癌给医疗保健带来了日益严峻的挑战。在长期随访的临床试验中，已确定在3/3.5周内进行15/16次每日分割的术后放疗的短疗程方案是安全有效的，并已成为大多数老年患者保乳治疗后的标准治疗方案。新出现的临床试验数据正在将短疗程放疗的极限推向一周内更短的方案。在这篇小型综述中，讨论了这些新数据对老年患者的适用性，以及针对该年龄组制定适应COVID-19大流行的短疗程剂量分割方案指南的情况。
